Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

over existing therapeutic approaches for Crohn's disease by potentially offering reduced side effects and convenient oral dosing to patients. Traficet-EN is being developed under a strategic alliance with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD).

About Crohn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  When Ryan Rendino first felt the ... neck, he figured it was a muscle ... from weight lifting. But the ... A series of doctor appointments followed ... Michel Kliot, MD , a Northwestern ...
(Date:5/21/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that its Board ... the second quarter 2015 of $0.03 per share of ... per share will be paid on June 19, 2015 ... 12, 2015.  The ex-dividend date for the quarterly dividend ...
(Date:5/21/2015)... Mai 2015 Dipexium Pharmaceuticals, ... Unternehmen für Arzneimittel im fortgeschrittenen Entwicklungsstadium, ... Vermarktung von Locilex® (Pexiganan-Creme 0,8 %) und ... wissenschaftliche Posterpräsentation an, welche das innovative ... OneStep-1 und OneStep-2, in der Locilex® ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... a global leader in minimally invasive cryotherapy treatments for ... establishing its new Global Headquarters in Minneapolis, MN. ... in Arden Hills during the fourth quarter of 2009. ... functions, the company will also locate its global marketing, ...
... alternative therapy for Parkinson,s , NEW YORK, Sept. 30 ... Center have reached a milestone in the development of potential ... of current therapy. , The team, which received an MJFF ... LEAPS (Linked Efforts to Accelerate Parkinson,s Solutions) initiative, ...
Cached Medicine Technology:Galil Medical Announces Establishment of Global Headquarters in Minneapolis, MN 2Michael J. Fox Foundation-Funded Team Pursuing Glutamate-Based Treatment for Parkinson's Disease Hits Major Milestone 2
(Date:5/24/2015)... Indiana Fiber Network, LLC (IFN), the ... of America, Inc. (MTA) has selected IFN as a ... IFN Enterprise Sales Manager, fiber route diversity and network ... transport provides MTA with the diverse fiber transport from ... Internet and voice carriers located at Henry Street in ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized ... power learned through meditation and initiation at Special Holistic ... , Yogamaatha, a nine-year-old girl from North Carolina, stunned ... attending the 2015 Business Advocacy Summit at Capitol Hill ... , In a demonstration that lasted three hours, Yogamaatha ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Manufacturers are now ... Performance Factor (HSPF) of 8.2. Experts in the field agree ... benefit consumers. , The HSPF score is what miles per ... more efficient the unit. Although the minimum HSPF score has ... heaters with an HSPF score north of 12. Indeed, the ...
(Date:5/22/2015)... Calif. (PRWEB) May 22, 2015 ... technology, communication and capacity are intersecting to create ... across society, the opening speaker at WesternU's 34th ... California Lieut. Gov. Gavin Newsom, a former San ... the keynote speaker at the graduation ceremony for ...
(Date:5/22/2015)... New York (PRWEB) May 22, 2015 ... ) filed on behalf of individuals who allegedly ... to its use continue to move forward in ... According to a Pretrial Order dated May 4, ... preservation of documents and electronically stored information. Among ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4
... finds no connection between the two , , MONDAY, Jan. ... of evidence that rejects the idea that immunizations boost ... incidences of the disorder dropped after makers of most ... products. , Researchers found that autism rates in California ...
... prescriptions for children and adults , , MONDAY, Jan. 7 ... thoughts and behaviors in young people who take antidepressants ... research suggests. , The U.S. Food and Drug Administration ... selective serotonin reuptake inhibitors (SSRIs) might increase the risk ...
... for Emageon presentation, BIRMINGHAM, Ala., Jan. 7 ... in enterprise medical information technology,systems for hospitals, healthcare ... Chairman, CEO and President, will present at the,26th ... January 7-10, 2008,at the Westin St. Francis Hotel ...
... PARK, Calif., Jan. 7 ForSight Labs, LLC announced,today ... VISION3,Inc. with a Series A financing of $6 million, ... the medical technology arena: Morgenthaler,Ventures, Split Rock Partners and ... a significant round of funding to,develop our next innovative ...
... Va., Jan. 7 Specialty Blades, Inc. and ... completed its,acquisition of Popper and Sons, Inc. The ... tubing medical device manufacturing company,makes the combined company ... for the medical device industry. Specialty Blades,originally announced ...
... kept exam dates, study finds , , MONDAY, Jan. 7 ... time in the short-term, people who do so tend not ... Time saved with an Internet purchase may translate into ... that people purchasing lenses from wholesale clubs or optical chains ...
Cached Medicine News:Health News:Study Casts Doubt on Vaccine-Autism Link 2Health News:Study Casts Doubt on Vaccine-Autism Link 3Health News:Youth Suicide Warnings Are Slowing Antidepressant Sales 2Health News:ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding 2Health News:ForSight Labs, LLC Announces Formation of Its Third Company, ForSight VISION3, Inc. and Closing of $6 Million in Series A Funding 3Health News:Eye Care Lacking in Many Who Buy Contact Lenses Online 2
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
... The Stryker Cross-Screw System offers ... secure method for ACL reconstruction ... Stryker Cross-Screw System provides the ... The implant comes in Titanium ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
The Stryker Shoulder Instrumentation Set is ideal for open and arthroscopic shoulder procedures. The kit includes all the necessary tools for bone and tissue preparation as well as suture management ...
Medicine Products: